SCHEMBL25792508

SCHEMBL25792508

c1ccc2c(c1)[nH]c1cc3[nH]c4ccccc4c3c(CCCn3cncn3)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGLN3 Q9H6Z9 1/20 0.47
▸ TSHR P16473 2/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ LMNA P02545 3/20 0.40
▸ MAPT P10636 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ CYP19A1 P11511 3/20 0.37
▸ ALDH1A1 P00352 2/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23875457 0.79 ALDH1A1 (0.48) EGLN3TSHRKDM4ELMNAMAPT
SCHEMBL23875628 0.72 ALDH1A1 (0.44) EGLN3TSHRKDM4ELMNAMAPT
SCHEMBL23875552 0.70 MAPT (0.40) EGLN3TSHRKDM4ELMNAMAPT
SCHEMBL25798557 0.69 CYP19A1 (0.43) EGLN3TSHRKDM4ELMNAMAPT
SCHEMBL6648239 0.69 CYP19A1 (0.62) EGLN3TSHRKDM4ELMNAMAPT
SCHEMBL23875574 0.68 LMNA (0.39) EGLN3TSHRKDM4ELMNAMAPT
SCHEMBL735834 0.67 HTR2A (0.54) EGLN3KDM4EMAPTMEN1KMT2A
SCHEMBL30059669 0.67 EGLN3 (0.44) EGLN3KDM4EMAPTMAPK1TP53
SCHEMBL30058010 0.67 EGLN3 (0.41) EGLN3TSHRKDM4ELMNAMAPT
SCHEMBL23875666 0.67 EGLN3 (0.44) EGLN3KDM4EMAPTMAPK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230174485-A1 LIPOXYGENASE INHIBITORS SRI INTERNATIONAL (US) 2023-06-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174485-A1 LIPOXYGENASE INHIBITORS ALOX15B, ALOX12, ALOX15 EGLN3 752/4885TSHR 4445/4885KDM4E 1282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback